drugset / Trial / NCT00468715
Bicalutamide in Treating Patients With Metastatic Breast Cancer
Phase 2
Completed
28 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens. PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients with metastatic breast cancer.
Timeline
- Start
- 2007-03-23
- Primary completion
- 2021-06-24
- Completion
- 2021-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 150 mg | Oral |